High-Risk Brain Research Wins NSF Backing
By Sara Reardon,
Nature News
| 08. 18. 2014
The National Science Foundation's (NSF’s) role in the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is starting to take shape. On 18 August, the NSF awarded 36 grants totalling US$10.8 million to projects studying topics ranging from electrodes that measure chemical and electrical signals to artificial-intelligence programs that can identify brain structures.
The three agencies participating in the BRAIN Initiative have taken markedly different approaches. The Defense Advanced Research Projects Agency, which received $50 million this year for the neuroscience initiative, is concentrating on implants and treatments for brain disorders that affect soldiers and veterans, such as post-traumatic stress disorder. It has already awarded multi-million dollar grants to several teams. The National Institutes of Health (NIH), which received $40 million this year, has put together a 146-page plan to map and observe the brain over the next decade, and will announce its first round of grant recipients next month.
The NSF, by contrast, has cast a wider net. The agency sent a request in March for informal, two-page project ideas. The only criterion was that the projects somehow address...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...